Frédérique Berger

2.1k total citations
64 papers, 1.0k citations indexed

About

Frédérique Berger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Frédérique Berger has authored 64 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Frédérique Berger's work include Advanced Breast Cancer Therapies (16 papers), BRCA gene mutations in cancer (12 papers) and PARP inhibition in cancer therapy (12 papers). Frédérique Berger is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), BRCA gene mutations in cancer (12 papers) and PARP inhibition in cancer therapy (12 papers). Frédérique Berger collaborates with scholars based in France, Belgium and United Kingdom. Frédérique Berger's co-authors include Bernard Asselain, Jean‐Yves Pierga, François‐Clément Bidard, Xavier Sastre‐Garau, Leanne de Koning, Alexia Savignoni, Geneviève Almouzni, Alain Fourquet, Delphine Loirat and Armelle Corpet and has published in prestigious journals such as Cell, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Frédérique Berger

60 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédérique Berger France	19	517	420	411	323	105	64	1.0k
Zachary A. Kohutek United States	11	494 1.0×	433 1.0×	358 0.9×	386 1.2×	107 1.0×	24	1.1k
Dina Leitão Portugal	14	673 1.3×	434 1.0×	296 0.7×	193 0.6×	129 1.2×	28	1.0k
Mateus Crespo United Kingdom	17	421 0.8×	399 0.9×	393 1.0×	525 1.6×	97 0.9×	44	1.0k
Marie‐Paule Sablin France	18	499 1.0×	410 1.0×	354 0.9×	289 0.9×	64 0.6×	50	942
Martina Storz Switzerland	17	326 0.6×	510 1.2×	255 0.6×	327 1.0×	75 0.7×	23	935
Veronique Neumeister United States	17	496 1.0×	510 1.2×	319 0.8×	170 0.5×	104 1.0×	35	968
Octavio Burgués Spain	21	522 1.0×	586 1.4×	673 1.6×	222 0.7×	77 0.7×	60	1.2k
S-A. Im South Korea	18	799 1.5×	324 0.8×	242 0.6×	454 1.4×	163 1.6×	85	1.1k
Cécile Vicier France	14	465 0.9×	338 0.8×	223 0.5×	229 0.7×	63 0.6×	53	808
Shyam M. Kavuri United States	10	751 1.5×	381 0.9×	383 0.9×	318 1.0×	245 2.3×	11	1.1k

Countries citing papers authored by Frédérique Berger

Since Specialization

Citations

This map shows the geographic impact of Frédérique Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérique Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérique Berger more than expected).

Fields of papers citing papers by Frédérique Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérique Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérique Berger. The network helps show where Frédérique Berger may publish in the future.

Co-authorship network of co-authors of Frédérique Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Frédérique Berger. A scholar is included among the top collaborators of Frédérique Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédérique Berger. Frédérique Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cabel, Luc, Frédérique Berger, Thomas Bachelot, et al.. (2025). Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. Annals of Oncology. 37(3). 329–340.

Loap, Pierre, Delphine Loirat, Marc‐Henri Stern, et al.. (2025). Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial. International Journal of Radiation Oncology*Biology*Physics. 123(3). 726–731. 2 indexed citations

Bidard, François‐Clément, Frédérique Berger, Mónica Arnedos, et al.. (2024). Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.. Journal of Clinical Oncology. 42(16_suppl). TPS1139–TPS1139. 1 indexed citations

Aktary, Zackie, et al.. (2024). UVB radiation suppresses Dicer expression through β-catenin. Journal of Cell Science. 137(22).

Camilleri, Géraldine M., Lidia Delrieu, Carole Bouleuc, et al.. (2024). Prevalence and survival implications of malnutrition and sarcopenia in metastatic breast cancer: A longitudinal analysis. Clinical Nutrition. 43(8). 1710–1718. 2 indexed citations

Buhagiar‐Labarchède, Géraldine, Rosine Onclercq-Delic, Sophie Vacher, et al.. (2022). Cytidine deaminase activity increases in the blood of breast cancer patients. Scientific Reports. 12(1). 14062–14062. 1 indexed citations

Vacher, Sophie, Charlotte Lecerf, Emmanuelle Jeannot, et al.. (2020). Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma. Cancer Biology and Medicine. 17(1). 208–217. 25 indexed citations

Frenel, Jean‐Sébastien, Florence Dalenc, Barbara Pistilli, et al.. (2020). 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial. Annals of Oncology. 31. S364–S364. 14 indexed citations

Cottu, Paul, Coraline Dubot, Laurence Venat‐Bouvet, et al.. (2017). Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial. Annals of Oncology. 28. v32–v32. 9 indexed citations

10.

Chevrier, Marion, Alain Fourquet, É. Costa, et al.. (2017). Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy. International Journal of Radiation Oncology*Biology*Physics. 98(1). 206–214. 22 indexed citations

11.

Dièras, Véronique, Frédérique Berger, Philippe Beuzeboc, et al.. (2017). First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. Anticancer Research. 37(3). 1403–1408. 6 indexed citations

12.

Bidard, François‐Clément, Étienne Brain, William Jacot, et al.. (2016). First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count. Annals of Oncology. 27. vi69–vi69. 1 indexed citations

13.

Hélissey, Carole, Frédérique Berger, Paul Cottu, et al.. (2015). Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial. Cancer Letters. 360(2). 213–218. 44 indexed citations

14.

Isaac, S., Évelyne Decullier, Alexandra Traverse‐Glehen, et al.. (2013). Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study. Annals of Surgical Oncology. 20(12). 3892–3898. 16 indexed citations

15.

Berger, Frédérique, Laurence Vaslin, Lisa Belin, et al.. (2013). The impact of single-nucleotide polymorphisms (SNPs) in OGG1 and XPC on the age at onset of Huntington disease. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 755(2). 115–119. 15 indexed citations

16.

Berger, Frédérique, et al.. (2011). Impact du statut socioéconomique sur la gravité du diagnostic initial de cancer du sein. Revue d Épidémiologie et de Santé Publique. 60(1). 19–29. 14 indexed citations

17.

Klijanienko, Jerzy, Jérôme Couturier, Hervé J. Brisse, et al.. (2011). Diagnostic and prognostic information obtained on fine‐needle aspirates of primary neuroblastic tumors. Cancer Cytopathology. 119(6). 411–423. 14 indexed citations

18.

Devun, Flavien, Guilhem Bousquet, J. Biau, et al.. (2011). Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. Journal of Gastroenterology. 47(3). 266–275. 18 indexed citations

19.

Corpet, Armelle, Leanne de Koning, Joern Toedling, et al.. (2010). Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. The EMBO Journal. 30(3). 480–493. 131 indexed citations

20.

Martín, F., et al.. (2006). A new micro minimally invasive biopsy tool for molecular analysis. PubMed. 2006. 2820–2823. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact